Johnson & Johnson (JNJ) Given Coverage Optimism Rating of 0.34

News stories about Johnson & Johnson (NYSE:JNJ) have trended positive recently, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Johnson & Johnson earned a media sentiment score of 0.34 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 47.3173986897464 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:

JNJ has been the topic of a number of research analyst reports. Cowen reiterated an “outperform” rating and set a $155.00 price objective (up previously from $147.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. UBS reiterated a “buy” rating and set a $148.00 price objective on shares of Johnson & Johnson in a research note on Thursday, August 31st. Jefferies Group raised their price objective on shares of Johnson & Johnson from $157.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, October 16th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Finally, Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the company an “outperform” rating in a research note on Thursday, October 19th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the company. Johnson & Johnson has a consensus rating of “Hold” and a consensus target price of $145.04.

Johnson & Johnson (JNJ) traded up $0.81 during trading on Friday, reaching $142.46. 12,012,749 shares of the company’s stock traded hands, compared to its average volume of 5,120,258. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. The firm has a market capitalization of $382,721.66, a price-to-earnings ratio of 19.95, a price-to-earnings-growth ratio of 2.90 and a beta of 0.80. Johnson & Johnson has a 12-month low of $110.76 and a 12-month high of $144.35.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same quarter in the previous year, the business posted $1.68 earnings per share. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. analysts predict that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.36%. The ex-dividend date was Monday, November 27th. Johnson & Johnson’s dividend payout ratio is 58.33%.

COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ) Given Coverage Optimism Rating of 0.34” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Insider Buying and Selling by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.

Leave a Reply